GLP-1 Receptor Agonists: What the Research Describes

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is any molecule that binds and activates the glucagon-like peptide-1 receptor (GLP-1R). The class takes its name from the native ligand: glucagon-like peptide-1, which Holst (source 1) described as a 30-amino-acid peptide produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon — the same precursor gene that yields glucagon in pancreatic alpha cells. Baggio and Drucker (source 2) grouped GLP-1 with glucose-dependent insulinotropic polypeptide (GIP) as the two incretins, peptides released from the gut in response to nutrient intake.

Every compound in the class shares that origin story, but almost none of them are the native sequence. The research literature on GLP-1 receptor agonists is, to a large degree, a literature about protein engineering: what researchers changed about a fragile 30-residue hormone to make it survive long enough to be studied.

Why is native GLP-1 a poor laboratory scaffold on its own?

Holst (source 1) reported that GLP-1 is “extremely rapidly metabolized and inactivated by the enzyme dipeptidyl peptidase IV even before the hormone has left the gut.” DPP-4 cleaves the peptide after the second residue, removing the N-terminal dipeptide that the receptor's activation mechanism depends on. The circulating half-life of the intact hormone is measured in minutes, not hours.

That single enzymatic vulnerability set the agenda for three decades of published chemistry. Two broad strategies emerged in the literature, and most named compounds combine both:

Sequence modification

Substituting the residue DPP-4 recognizes so the enzyme no longer cleaves the peptide. Lau et al. (source 5) documented an Aib (alpha-aminoisobutyric acid) substitution at position 8 for this purpose.

Protraction by carrier binding

Attaching a fatty acid, an antibody Fc domain, or albumin itself so the molecule is too large to be cleared quickly by the kidney and is reversibly sequestered in plasma. Knudsen and Lau (source 6) described reversible albumin binding as the mechanism used for both liraglutide and semaglutide.

Where did the first GLP-1 receptor agonist scaffold come from?

Not from human GLP-1. Eng and colleagues (source 3) isolated a 39-amino-acid peptide they named exendin-4 from the venom of Heloderma suspectum, the Gila monster, and published the work in the Journal of Biological Chemistry in 1992. In dispersed acini from guinea pig pancreas, natural and synthetic exendin-4 produced a monophasic increase in cAMP beginning at 100 pM and plateauing at 10 nM. Exendin-4 differs from the closely related exendin-3 by two substitutions, Gly2-Glu3 in place of Ser2-Asp3 — and that glycine at position 2 is what makes the venom peptide intrinsically resistant to DPP-4 cleavage.

The synthetic version of that sequence, exenatide, became the first GLP-1 receptor agonist approved for type 2 diabetes in 2005, according to the review by Nauck et al. (source 7). Every later compound in the class was measured against it.

What does structural biology show about the receptor itself?

Zhang et al. (source 4) reported a cryo-electron microscopy structure of the peptide-activated GLP-1R–G_s complex at near-atomic resolution in Nature in 2017. GLP-1R is a class B G-protein-coupled receptor that signals primarily through the stimulatory G protein G_s. In that structure the peptide sits clasped between the receptor's N-terminal domain and its transmembrane core, further stabilized by extracellular loops, and activation produces a sharp kink in the middle of transmembrane helix 6 whose intracellular half pivots outward to accommodate the alpha-5 helix of the G_s Ras-like domain.

Why this matters for anyone reading binding data: class B GPCRs recognize a long peptide across two separate surfaces, which is why relatively small sequence edits far from the N-terminus can still shift reported receptor affinity by an order of magnitude, and why affinity values differ between assay systems.

How do the compounds in the class differ from each other?

Nauck et al. (source 7) grouped the approved compounds by administration interval — twice daily (exenatide b.i.d.), once daily (lixisenatide, liraglutide), and once weekly (exenatide once weekly, dulaglutide, albiglutide, semaglutide) — and noted that a daily oral semaglutide preparation was subsequently approved. The table below summarizes how the published literature distinguishes the main scaffolds.

What figures did the semaglutide chemistry paper actually report?

Lau et al. (source 5) is the most quantitatively specific paper in the class and is worth reading in the original. Semaglutide carries two amino acid substitutions relative to human GLP-1 — Aib at position 8 and Arg at position 34 — and is derivatized at lysine 26. Its reported GLP-1R affinity was 0.38 ± 0.06 nM, a three-fold decrease compared with liraglutide, while its albumin affinity increased. In mini-pigs, researchers measured a plasma half-life of 46.1 hours after intravenous administration and a mean residence time of 63.6 hours after subcutaneous administration.

That trade-off is the central design finding of the class: the authors deliberately accepted lower receptor affinity in exchange for higher albumin affinity, because exposure over time, not peak potency, is what governs a once-weekly profile.

What are dual and triple receptor agonists?

The newer compounds in this literature are not GLP-1 receptor agonists in the narrow sense — they are multi-receptor peptides that include GLP-1R among their targets. Coskun et al. (source 8) described LY3298176 (tirzepatide) as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity, reporting that it activated both receptors in vitro and, in mice, decreased body weight and food intake to a significantly greater degree than a GLP-1 receptor agonist alone. The phase 1 program described in that paper enrolled 142 human subjects across single-ascending-dose and 4-week multiple-ascending-dose arms.

Coskun et al. (source 9) subsequently characterized LY3437943 (retatrutide) as a triple agonist at the glucagon receptor (GCGR), GIP receptor, and GLP-1 receptor, reporting balanced GCGR and GLP-1R activity with comparatively greater GIPR activity. In obese mice, the authors attributed the observed changes to a combination of GCGR-mediated increases in energy expenditure alongside GIPR- and GLP-1R-driven reductions in calorie intake. In a phase 1 single-ascending-dose study, reduced body weight persisted to day 43 after a single administration.

A separate line of work pairs GLP-1 receptor agonists with peptides that act on a different receptor family altogether: long-acting amylin analogues, which target the calcitonin receptor and its RAMP-containing amylin receptor variants rather than GLP-1R. One such peptide, studied alongside semaglutide in published combination trials, is covered in what research has described about cagrilintide.

What do the compounds in this class share mechanistically?

Nauck et al. (source 7) identified four actions common to all GLP-1 receptor agonists in the published record: augmentation of hyperglycemia-induced insulin secretion, suppression of glucagon secretion at hyper- or euglycemia, deceleration of gastric emptying, and a reduction in calorie intake and body weight. The same review noted that short-acting agents (exenatide twice daily, lixisenatide) and long-acting agents differ in which of these actions dominates.

Drucker (source 10) mapped the GLP-1R-positive cell types behind those signals, and Knudsen and Lau (source 6) noted that the receptor is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain — which is why the class's pharmacology in the literature extends well beyond the islet.

How are these peptides handled as research materials?

The laboratory handling questions do not change across the class. These peptides ship lyophilized, are typically stored at -20°C or colder before reconstitution, and are reconstituted with bacteriostatic water for bench work, with repeated freeze-thaw cycles avoided. The acylated compounds — liraglutide, semaglutide, tirzepatide, retatrutide — carry a fatty-acid side chain that makes reversed-phase HPLC retention behavior different from an unmodified peptide, which is one reason identity confirmation by mass spectrometry matters alongside a purity percentage.

Because the class is defined by small sequence edits — a single Aib substitution, one acylation site — batch-level verification is not optional for anyone comparing their results against published figures. Every Steadfast Research Group vial ships with a batch-matched Certificate of Analysis documenting identity by mass spectrometry and purity by HPLC, so the material in the freezer can be traced to the lot that was tested.